| Literature DB >> 33665092 |
Jang Won Lee1,2, Min Kyung Hyun2, Hye Jin Kim3, Dong-Il Kim4.
Abstract
BACKGROUND: Acupuncture and herbal medicine have been used as additional treatments for infertility or as an adjuvant treatment of assisted reproductive technology (ART) in infertility. Many systematic reviews (SRs) and meta-analyses (MA) have been published. This paper reviews the SRs and MA of acupuncture and herbal medicine on infertility to provide evidence for clinical decision making.Entities:
Keywords: Acupuncture; Herbal medicine; Infertility; Overview; Systematic review
Year: 2020 PMID: 33665092 PMCID: PMC7903059 DOI: 10.1016/j.imr.2020.100694
Source DB: PubMed Journal: Integr Med Res ISSN: 2213-4220
Fig. 1Flow-chart of literature search and study selection.
Characteristics of the systematic reviews of acupuncture and herbal medicine for infertile women (Please add the references).
| Author (year) Ref | Country | Number of RCT(Total population) | Infertile women | Intervention | Comparator | Outcome measure | |||
|---|---|---|---|---|---|---|---|---|---|
| CPR | OPR | LBR | Others | ||||||
| Cheong | UK | 13 ( | undergoing ART | AT | No treatment | √ | √ | √ | |
| El-Toukhy | UK | 13 ( | undergoing IVF | AT | No treatment | √ | √ | ||
| Manheimer | USA | 7 ( | no regstriction??? | AT | No treatment | √ | √ | √ | |
| Drake | USA | 4 ( | Reproductive-age undergoing IVF | AT | No treatment | √ | √ | ||
| Qu | China | 17 ( | undergoing IVF | AT | No treatment | √ | √ | √ | miscarriage, BPR, IR |
| Zheng | China | 24 ( | undergoing IVF | AT | No treatment | √ | √ | √ | BPR, IR, miscarriage, adverse effect |
| Cheong | UK | 20 ( | undergoing ART | AT | No treatment | √ | |||
| Manheimer | USA | 16 ( | no regstriction??? | AT | No treatment | √ | √ | √ | |
| Shen | China | 21 ( | undergoing IVF | AT | No treatment | √ | |||
| Hassanzadeh | Iran | 4 ( | no regstriction | AT | Placebo | STAI, 20-item STAI, HAS, Chinese version of STAI | |||
| Qian | China | 30 ( | undergoing IVF | AT | No treatment | √ | √ | √ | BPR |
| Schwarze | Chile | 6 ( | undergoing IVF | AT | No treatment | √ | √ | √ | |
| Zhang | China | 17 ( | Infertile women | AT | No treatment | √ | √ | √ | BPR, IR, miscarriage |
| Smith | Australia | 20 ( | Infertile women undergoing IVF | AT | No treatment | √ | |||
| Jo | Korea | 4 ( | PCOS undergoing IVF | AT | No treatment | √ | √ | ||
| Ried | Australia | 7 ( | Reproductive-age | HM only | WM | √ | |||
| HM+AT | |||||||||
| HM +WM | |||||||||
| Ried | Australia | 40 ( | Reproductive-age | HM | WM | √ | |||
| Cao | China | 20 ( | undergoing IVF | HM +IVF | IVF | √ | √ | √ | |
| Zhou | China | 5 ( | PCOS | HM | No treatment | √ | ovulation rate, adverse effect | ||
| Bae | Korea | 8 ( | PCOS | Herbal medicine | No treatment | √ | √ | ||
| Tan | China | 15 ( | Anovulation | HM | No treatment | √ | √ | ovulation rate | |
ART, assisted reproductive technology; AT: acupuncture; BPR, biological pregnancy rate; CPR, clinical pregnancy rate; HM: herbal medicine; IR, implantation rate; IVF, in vitro fertilization; LBR, live birth rate; OPR, ongoing pregnancy rate; PCOS, polycystic ovary syndrome; WM, western medicine pharmacological treatment.
The results of meta-analysis of the included systematic reviews for each outcome related with infertility.
| Author (year) ref | Intervention | Comparisons | Statistical Model | Pooled effect [95% CI] (I2) |
|---|---|---|---|---|
| Acupuncture for infertility women undergoing IVF | ||||
| Cheong (2008) | Acupuncture on the day of ET ( | No acupuncture ( | RE | 1.26 [0.85–1.88] (59%) |
| Cheong (2008) | Repeated acupuncture ( | No acupuncture ( | FE | 2.23 [1.41–3.51] (0%) |
| Cheong (2008) | Acupuncture around the time of OR ( | No acupuncture ( | RE | 1.14 [0.76–1.72] (48%) |
| El-Toukhy (2008) | Acupuncture around the time of TVOR ( | Control ( | RE | 1.06 [0.82–1.37] (44.5%) |
| El-Toukhy (2008) | Acupuncture around the time of ET ( | Control ( | RE | 1.23 [0.96–1.58] (68.2%) |
| Manheimer (2008) | Acupuncture ( | Control ( | RE | 1.65 [1.27–2.14] (16%) |
| Drake (2011) | Acupuncture | Lying | NR | NR |
| Drake (2011) | Acupuncture | Streitberger placebo needling | NR | NR |
| Drake (2011) | Acupuncture | Non-qi needling | NR | NR |
| Qu (2012) | Acupuncture ( | Control ( | RE | 1.09 [0.94–1.26] (62.2%) |
| Zheng (2012) | Acupuncture ( | Control ( | RE | 1.22 [1.01–1.47] (58%) |
| Manheimer (2013) | Acupuncture ( | Control ( | RE | 1.12 [0.96–1.31] (68%) |
| Zheng (2012) | Acupuncture ( | Control except Streitberger control ( | RE | 1.34 [1.08–1.67] (52%) |
| Shen (2015) | Acupuncture ( | No intervention control ( | RE | 1.24 [1.02–1.50] (64%) |
| Shen (2015) | Acupuncture ( | Sham acupuncture ( | RE | 1.03 [0.87–1.22] (59%) |
| Qian (2017) | Acupuncture ( | Control ( | RE | 1.26 [1.06–1.50] (55%) |
| Schwarze (2018) | Acupuncture on the day of ET ( | Control ( | FE | 0.87 [0.77- 0.98] (19%) |
| Zhang (2018) | Acupuncture (NR) | Control (NR) | RE | 1.19 [1.06–1.34] (63.4%) |
| Smith (2019) | Acupuncture ( | Sham control ( | RE | 1.07 [0.88–1.30] (67%) |
| Smith (2019) | Acupuncture ( | No treatment ( | RE | 1.32 [1.07–1.62] (61%) |
| Cheong (2008) | Acupuncture on the day of ET ( | Control ( | RE | 1.38 [0.78–2.44] (71%) |
| Cheong (2008) | Repeated acupuncture ( | Control ( | RE | 1.79 [0.93–3.44] (45%) |
| Cheong (2008) | Acupuncture around the time of OR ( | Control ( | FE | 0.86 [0.58–1.26] (0%) |
| Manheimer (2008) | Acupuncture ( | Control ( | RE | 1.87 [1.40–2.49] (0%) |
| Manheimer (2013) | Acupuncture ( | Control ( | RE | 1.22 [0.98–1.52] (69%) |
| Qian (2017) | Acupuncture ( | Control ( | RE | 1.14 [0.87–1.48] (63%) |
| Zhang (2018) | Acupuncture (NR) | Control (NR) | RE | 1.21 [0.95–1.55] (67.1%) |
| Smith (2019) | Acupuncture ( | Sham control ( | FE | 0.98 [0.86–1.13] (72%) |
| Smith (2019) | Acupuncture ( | No treatment ( | FE | 1.42 [1.17–1.73] (0%) |
| Cheong (2008) | Acupuncture on the day of ET ( | Control ( | FE | 1.86 [1.27–2.73] (0%) |
| Cheong (2008) | Repeated acupuncture ( | Control ( | RE | 1.79 [0.93–3.44] (45%) |
| Cheong (2008) | Acupuncture around the time of OR ( | Control ( | FE | 0.87 [0.59–1.29] (0%) |
| Manheimer (2008) | Acupuncture ( | Control ( | RE | 1.91 [1.39–2.64] (0%) |
| Drake (2011) | Acupuncture | Strietberger placebo needling | NR | NR |
| Qu (2012) | Acupuncture ( | Control ( | RE | 1.42 [0.92–2.20] (86.5%) |
| Zheng (2012) | Acupuncture ( | Control ( | FE | 1.09 [0.74–1.60] (69%) |
| Zheng (2012) | Acupuncture ( | Control except Streitberger control ( | FE | 1.63 [1.16–2.30] (22%) |
| Cheong (2013) | Acupuncture around the time of OR ( | Control ( | FE | 0.87 [0.59–1.29] (0%) |
| Cheong (2013) | Acupuncture around the day of ET ( | Control ( | RE | 1.22 [0.87–1.70] (69%) |
| Manheimer (2013) | Acupuncture ( | Control ( | RE | 1.14 [0.92–1.42] (68%) |
| Qian (2017) | Acupuncture ( | Control ( | RE | 1.17 [0.80–1.72] (74%) |
| Zhang (2018) | Acupuncture (NR) | Control (NR) | RE | 1.36 [1.09–1.69] (70.1%) |
| Smith (2019) | Acupuncture ( | Sham control ( | RE | 1.01 [0.80–1.28] (64%) |
| Smith (2019) | Acupuncture ( | No treatment ( | RE | 1.30 [1.00–1.68] (63%) |
| Cheong (2008) | Acupuncture on the day of ET ( | Control ( | FE | 0.88 [0.35–2.22] (0%) |
| Cheong (2008) | Repeated acupuncture ( | Control ( | FE | 1.68 [0.90–3.12] (0%) |
| Cheong (2008) | Acupuncture around the time of OR ( | Control ( | FE | 0.81 [0.46–1.46] (0%) |
| Qu (2012) | Acupuncture ( | Control ( | RE | 0.95 [0.68–1.35] (0%) |
| Cheong (2013) | Acupuncture around the time of OR ( | Control ( | FE | 0.79 [0.42–1.47] (17%) |
| Cheong (2013) | Acupuncture around the day of ET ( | Control ( | FE | 1.10 [0.73–1.67] (0%) |
| Manheimer (2013) | Acupuncture ( | Control ( | RE | 1.09 [0.85–1.40] (0%) |
| Zhang (2018) | Acupuncture (NR) | Control (NR) | RE | 0.89 [0.67–1.20] (0%) |
| Smith (2019) | Acupuncture ( | Sham control ( | RE | 1.15 [0.78–1.67] (28%) |
| Smith (2019) | Acupuncture ( | No treatment ( | RE | 1.43 [1.03–1.98] (0%) |
| Qu (2012) | Acupuncture ( | Control ( | RE | 1.01 [0.84–1.20] (73.7%) |
| Qian (2017) | Acupuncture ( | Control ( | RE | 1.06 [0.82–1.37] (69%) |
| Qu (2012) | Acupuncture ( | Control ( | RE | 1.22 [0.93–1.62] (69.8%) |
| Zhang (2018) | Acupuncture (NR) | Control (NR) | RE | 1.31 [1.08–1.59] (68.5%) |
| Jo (2017) | Acupuncture ( | Control ( | RE | 1.33 [1.03–1.71] (0%) |
| Jo (2017) | Acupuncture ( | Control ( | RE | 2.03 [1.08–3.81] (0%) |
| Ried (2011) | Herbal medicine ( | WM fertility medication ( | RE | 3.50 [2.34–5.24] (42%) |
| Ried (2015) | Herbal medicine ( | Control ( | RE | 1.74 [1.56–1.94] (50%) |
| Cao (2013) | Herbal medicine (NR) | Control (NR) | RE | 2.04 [1.67–2.49] (0%) |
| Cao (2013) | Herbal medicine (NR) | Control (NR) | RE | 1.91 [1.17–3.10] (0%) |
| Cao (2013) | Herbal medicine (NR) | Control (NR) | RE | 1.64 [1.33–2.01] (0%) |
| Cao (2013) | Herbal medicine (NR) | Control (NR) | RE | 0.39 [0.14–1.11] (0%) |
| Zhou (2016) | Herbal medicine +clomiphene | clomiphene | FE | 2.62 [1.65–4.14] (0%) |
| Bae (2017) | Herbal medicine +WM ( | WM ( | RE | 2.33 [1.53–3.54] (0%) |
| Tan (2012) | Herbal medicine ( | Clomiphene ( | FE | 3.12 [2.50–3.88] (12%) |
| Tan (2012) | Herbal medicine ( | Clomiphene combination therapy ( | FE | 2.12 [0.98–4.57] (0%) |
Abbreviations: ET, embryo transfer; FE, fixed effect; IVF, in vitro fertilization; NR, not report; OR, oocyte retrieval; PCOS, polycystic ovary syndrome; RE, random effect; TVOR, time of transvaginal oocyte retrieval; WM, western medicine.